Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 49 to 52 of 52 entries
Sorted by: Best Match Show Resources per page
Histamine Regulates the Inflammatory Profile of SOD1-G93A Microglia and the Histaminergic System Is Dysregulated in Amyotrophic Lateral Sclerosis.

Frontiers in immunology

Apolloni S, Fabbrizio P, Amadio S, Napoli G, Verdile V, Morello G, Iemmolo R, Aronica E, Cavallaro S, Volonté C.
PMID: 29250069
Front Immunol. 2017 Nov 30;8:1689. doi: 10.3389/fimmu.2017.01689. eCollection 2017.

Amyotrophic lateral sclerosis (ALS) is a late-onset motor neuron disease where activated glia release pro-inflammatory cytokines that trigger a vicious cycle of neurodegeneration in the absence of resolution of inflammation. Given the well-established role of histamine as a neuron-to-glia...

Cite
Apolloni S, Fabbrizio P, Amadio S, et al. Histamine Regulates the Inflammatory Profile of SOD1-G93A Microglia and the Histaminergic System Is Dysregulated in Amyotrophic Lateral Sclerosis. Front Immunol. 2017;8:1689doi: 10.3389/fimmu.2017.01689.
Apolloni, S., Fabbrizio, P., Amadio, S., Napoli, G., Verdile, V., Morello, G., Iemmolo, R., Aronica, E., Cavallaro, S., & Volonté, C. (2017). Histamine Regulates the Inflammatory Profile of SOD1-G93A Microglia and the Histaminergic System Is Dysregulated in Amyotrophic Lateral Sclerosis. Frontiers in immunology, 81689. https://doi.org/10.3389/fimmu.2017.01689
Apolloni, Savina, et al. "Histamine Regulates the Inflammatory Profile of SOD1-G93A Microglia and the Histaminergic System Is Dysregulated in Amyotrophic Lateral Sclerosis." Frontiers in immunology vol. 8 (2017): 1689. doi: https://doi.org/10.3389/fimmu.2017.01689
Apolloni S, Fabbrizio P, Amadio S, Napoli G, Verdile V, Morello G, Iemmolo R, Aronica E, Cavallaro S, Volonté C. Histamine Regulates the Inflammatory Profile of SOD1-G93A Microglia and the Histaminergic System Is Dysregulated in Amyotrophic Lateral Sclerosis. Front Immunol. 2017 Nov 30;8:1689. doi: 10.3389/fimmu.2017.01689. eCollection 2017. PMID: 29250069; PMCID: PMC5714870.
Copy Download .nbib Format: NLM
Three-electron auger process from beam-foil excited multiply charged ions.

Physical review letters

De Filippo E, Lanzanò G, Rothard H, Volant C.
PMID: 18643496
Phys Rev Lett. 2008 Jun 13;100(23):233202. doi: 10.1103/PhysRevLett.100.233202. Epub 2008 Jun 13.

Electron emission from collisions of C3+ ions (22.7 A MeV) with carbon foils (21, 49 and 90 microg/cm(2)) was studied by the time-of-flight method. Two prominent emission patterns can be readily identified as "binary encounter" electrons and "cusp" electrons....

Cite
De Filippo E, Lanzanò G, Rothard H, et al. Three-electron auger process from beam-foil excited multiply charged ions. Phys Rev Lett. 2008;100(23):233202doi: 10.1103/PhysRevLett.100.233202.
De Filippo, E., Lanzanò, G., Rothard, H., & Volant, C. (2008). Three-electron auger process from beam-foil excited multiply charged ions. Physical review letters, 100(23), 233202. https://doi.org/10.1103/PhysRevLett.100.233202
De Filippo, Enrico, et al. "Three-electron auger process from beam-foil excited multiply charged ions." Physical review letters vol. 100,23 (2008): 233202. doi: https://doi.org/10.1103/PhysRevLett.100.233202
De Filippo E, Lanzanò G, Rothard H, Volant C. Three-electron auger process from beam-foil excited multiply charged ions. Phys Rev Lett. 2008 Jun 13;100(23):233202. doi: 10.1103/PhysRevLett.100.233202. Epub 2008 Jun 13. PMID: 18643496.
Copy Download .nbib Format: NLM
Drug Repurposing: A Network-based Approach to Amyotrophic Lateral Sclerosis.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

Fiscon G, Conte F, Amadio S, Volonté C, Paci P.
PMID: 33987813
Neurotherapeutics. 2021 Jul;18(3):1678-1691. doi: 10.1007/s13311-021-01064-z. Epub 2021 May 13.

The continuous adherence to the conventional "one target, one drug" paradigm has failed so far to provide effective therapeutic solutions for heterogeneous and multifactorial diseases as amyotrophic lateral sclerosis (ALS), a rare progressive and chronic, debilitating neurological disease for...

Cite
Fiscon G, Conte F, Amadio S, et al. Drug Repurposing: A Network-based Approach to Amyotrophic Lateral Sclerosis. Neurotherapeutics. 2021;18(3):1678-1691doi: 10.1007/s13311-021-01064-z.
Fiscon, G., Conte, F., Amadio, S., Volonté, C., & Paci, P. (2021). Drug Repurposing: A Network-based Approach to Amyotrophic Lateral Sclerosis. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 18(3), 1678-1691. https://doi.org/10.1007/s13311-021-01064-z
Fiscon, Giulia, et al. "Drug Repurposing: A Network-based Approach to Amyotrophic Lateral Sclerosis." Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics vol. 18,3 (2021): 1678-1691. doi: https://doi.org/10.1007/s13311-021-01064-z
Fiscon G, Conte F, Amadio S, Volonté C, Paci P. Drug Repurposing: A Network-based Approach to Amyotrophic Lateral Sclerosis. Neurotherapeutics. 2021 Jul;18(3):1678-1691. doi: 10.1007/s13311-021-01064-z. Epub 2021 May 13. PMID: 33987813; PMCID: PMC8609089.
Copy Download .nbib Format: NLM
Repurposing of Trimetazidine for amyotrophic lateral sclerosis: A study in SOD1.

British journal of pharmacology

Scaricamazza S, Salvatori I, Amadio S, Nesci V, Torcinaro A, Giacovazzo G, Primiano A, Gloriani M, Candelise N, Pieroni L, Loeffler JP, Renè F, Quessada C, Tefera TW, Wang H, Steyn FJ, Ngo ST, Dobrowolny G, Lepore E, Urbani A, Musarò A, Volonté C, Ferraro E, Coccurello R, Valle C, Ferri A.
PMID: 34783031
Br J Pharmacol. 2021 Nov 16; doi: 10.1111/bph.15738. Epub 2021 Nov 16.

BACKGROUND AND PURPOSE: Amyotrophic lateral sclerosis (ALS), a neurodegenerative disease characterized by the degeneration of upper and lower motor neurons, progressive wasting and paralysis of voluntary muscles and is currently incurable. Although considered to be a pure motor neuron...

Cite
Scaricamazza S, Salvatori I, Amadio S, et al. Repurposing of Trimetazidine for amyotrophic lateral sclerosis: A study in SOD1. Br J Pharmacol. 2021;doi: 10.1111/bph.15738.
Scaricamazza, S., Salvatori, I., Amadio, S., Nesci, V., Torcinaro, A., Giacovazzo, G., Primiano, A., Gloriani, M., Candelise, N., Pieroni, L., Loeffler, J. P., Renè, F., Quessada, C., Tefera, T. W., Wang, H., Steyn, F. J., Ngo, S. T., Dobrowolny, G., Lepore, E., Urbani, A., Musarò, A., Volonté, C., Ferraro, E., Coccurello, R., Valle, C., & Ferri, A. (2021). Repurposing of Trimetazidine for amyotrophic lateral sclerosis: A study in SOD1. British journal of pharmacology, . https://doi.org/10.1111/bph.15738
Scaricamazza, Silvia, et al. "Repurposing of Trimetazidine for amyotrophic lateral sclerosis: A study in SOD1." British journal of pharmacology vol. (2021). doi: https://doi.org/10.1111/bph.15738
Scaricamazza S, Salvatori I, Amadio S, Nesci V, Torcinaro A, Giacovazzo G, Primiano A, Gloriani M, Candelise N, Pieroni L, Loeffler JP, Renè F, Quessada C, Tefera TW, Wang H, Steyn FJ, Ngo ST, Dobrowolny G, Lepore E, Urbani A, Musarò A, Volonté C, Ferraro E, Coccurello R, Valle C, Ferri A. Repurposing of Trimetazidine for amyotrophic lateral sclerosis: A study in SOD1. Br J Pharmacol. 2021 Nov 16; doi: 10.1111/bph.15738. Epub 2021 Nov 16. PMID: 34783031.
Copy Download .nbib Format: NLM
Showing 49 to 52 of 52 entries